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Background: Simvastatin increases the expression of bone morphogenetic protein 2 (BMP-2) in osteoblasts,
therefore it is important to investigate the influence of statins on bone formation, fracture healing and implant
integration. The aim of the present study was to investigate the effect of Simvastatin, locally applied from
intramedullary coated and bioactive implants, on bone integration using biomechanical and histomorphometrical
analyses.
Methods: Eighty rats received retrograde nailing of the femur with titanium implants: uncoated vs. polymer-only
(poly(D,L-lactide)) vs. polymer plus drug coated (either Simvastatin low- or high dosed; “SIM low/ high”). Femurs
were harvested after 56 days for radiographic and histomorphometric or biomechanical analysis (push-out).
Results: Radiographic analysis revealed no pathological findings for animals of the control and SIM low dose group.
However, n=2/10 animals of the SIM high group showed osteolysis next to the implant without evidence of
bacterial infection determined by microbiological analysis. Biomechanical results showed a significant decrease in
fixation strength for SIM high coated implants vs. the control groups (uncoated and PDLLA). Histomorphometry
revealed a significantly reduced total as well as direct bone/implant contact for SIM high- implants vs. controls
(uncoated and PDLLA-groups). Total contact was reduced for SIM low vs. uncoated controls. Significantly reduced
new bone formation was measured around SIM high coated implants vs. both control groups.
Conclusions: This animal study suggests impaired implant integration with local application of Simvastatin from
intramedullary titanium implants after 8 weeks when compared to uncoated or carrier-only coated controls.
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The increasing number of primary and revision surgeries
following orthopaedic implant application suggests the
need for a durable osseous integration. Optimal osseointe-
gration depends on the formation of new bone around
orthopaedic implants, which may be stimulated by
osteoinductive agents.
One safe [1] and promising substance group for this
aim are the statins, where were primarily developed to
inhibit cholesterol biosynthesis [2] and reduce its plasma
levels [3]. Besides other pleiotropic effects [4,5], Simvastatin
furthermore stimulates bone formation in a human* Correspondence: stephan.pauly@charite.de
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reproduction in any medium, provided the orosteoblast cell line (MG-63) via increased expression
of bone morphogenetic protein (BMP-2) [6]. BMP-2
is one of the most potent growth factors targeting bone
formation in vivo [7], which stimulates osteoblast differ-
entiation and -proliferation [8-10].
With systemic [11-14] or local delivery of statins to the
bone from biodegradable carriers or percutaneous appli-
cation forms, bone formation and fracture healing were
improved in several experimental investigations [15-22].
Statins were also shown to improve implant integration
following arthroplastic surgery. Although there have been
multiple studies using systemic administration [11,23-25],
only a few studies have investigated local application of
statin-containing gels or microspheres and their effect on
implant-bone integration [26-28]. In summary, combining
the bone anabolic effect of Simvastatin with other localtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Local application seems to be a reasonable strategy,
as statins target liver metabolism and are poorly distribu-
ted to bone due to first pass elimination [29]. Further-
more, local application helps prevent systemic side effects
of drugs.
Hence, it was the aim of the present study to investi-
gate the effect of Simvastatin, locally applied in a bio-
degradable Poly(D,L-lactide) coating from intramedullary
implants [30], on bone integration using biomechanical
and histomorphometrical analyses.
We hypothesized that Simvastatin would improve
histomorphometrical and biomechanical implant inte-
gration when compared to uncoated or carrier only-
coated devices.
Results
There were no differences in body temperature and -weight
between the groups over the experimental time
period. None of the animals showed evidence of local
or systemic infection throughout the experimental
period.
After 56 days at the x-ray control, no radiographic im-
plant dislocation was observed (Figure 1). However,
n=2/20 animals of the SIM high-group showed osteolysis
around the implants (Figure 2) and n=1/20 animal fromFigure 1 Histomorphometric overview and x-ray after 56 days, for an
high. No macroscopic differences were obvious between all 4 groups with
implant loosening.both the PDLLA and SIM high group had broadened
medullary canals. However, microbiological analysis of
these affected femurs showed no evidence of bacterial
infections.
Calculated strength of fixation was highest for uncoated
implants when compared to all other control and experi-
mental groups. Fixation of SIM high coated implants was
significantly weaker than with uncoated- (p = 0.002) or
PDLLA-coated implants (p = 0.005, Figure 3).
Histomorphometrical analysis with regard to total
bone/implant contact showed only marginal differences
between the control groups (uncoated, PDLLA-coated,
Figure 4). However, lower results were detected for both
experimental groups, reaching level of significance for
SIM high when compared to both control groups (minus
46.0% and 32.8%, respectively, p < 0.001) and for SIM
low vs. uncoated controls (p = 0.006).
Neither direct nor indirect bone/implant contact
differed significantly between uncoated and PDLLA-
coated implants. In terms of direct contact, SIM high
results were significantly decreased when compared to
both control groups (vs. uncoated: p = 0.001; vs.
PDLLA: p = 0.006; Figure 4).
Indirect contact was highest in the uncoated and
PDLLA-coated groups. Both SIM coated groups had
lower values than the controls, differing significantlyimals from a) uncoated group, b) PDLLA, c) SIM low and d) SIM
regard to implant integration, osteolysis, ectopic bone formation or
Figure 2 Microscopic and radiographic findings in one (out of n=2/20) SIM high-treated femur after 56 days, showing osteolysis
around the implant. Bacterial infection was ruled out by means of microbiological diagnostics.
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p = 0.004, Figure 4).
Assessment of newly formed bone around the implants
revealed significant reduction for the groups PDLLA (p =
0.002) and SIM low and -high (p < 0.001, respectively)
when compared to uncoated controls (Figure 4). SIM high
implants showed significantly less surrounding new bone
than PDLLA-coated implants (p = 0.002).Discussion
The present findings suggest impaired implant integra-
tion with local application of Simvastatin from intrame-
dullary titanium implants after 8 weeks when compared
to uncoated or carrier-only coated controls.
Though the two cases of radiographic osteolysis around
the implant occured in the histomorphometric group,
biomechanical stability was significantly weaker for SIM
high when compared to uncoated and carrier-only coated
implants. Histomorphometry confirmed a significant re-
duction in total bone/implant contact, (in-)direct contactFigure 3 Biomechanical fixation strength of SIM high coated implants
PDLLA-coated implants (p = 0.005) (*).and new bone formation for the experimental groups
when compared to the control groups.
In summary, the hypothesis of the present paper with
regard to improved implant integration must be rejected
for both experimental groups.
The question arises why bone integrational processes
deteriorated under Simvastatin exposure when com-
pared to controls. One potential obvious explanation,
intramedullary infections of the femurs, was ruled out
since no bacteria were identified after microbiological
analysis over 14 days.
Another possible reason for the adverse effects might
be the PDLLA-coating itself. However, this polymer was
previously shown to be biocompatible, mechanically
stable [30] and a reproducibly degradable carrier to
locally deliver agents to the bone, without evidence of
osteolysis [20,31-34]. Furthermore, the PDLLA-group
showed (significantly) superior biomechanical, histomor-
phometric and radiographic properties when compared
to the experimental groups. Thus, PDLLA is likely not
the reason for the deteriorated bone integration, evenwas significantly weaker than with uncoated- (p = 0.002) or
Figure 4 a) Histomorphometric analysis. Total bone/implant contact was significantly decreased between the uncoated control and both
experimental groups (SIM high: p < 0.001; SIM low: p = 0.006) as well as between PDLLA and SIM high (p < 0.001) (*). b) Direct bone/implant
contact showed significant differences between SIM high and both control groups (vs. uncoated: p = 0.001; vs. PDLLA: p = 0.006) (*). c) Indirect
bone/implant contact was reduced for both SIM coated groups, differing significantly between the PDLLA and SIM high group (p = 0.004) (*).
d) Newly formed bone (within a 0.3mm range around the implants) was significantly reduced between uncoated controls and all other groups
(vs. PDLLA: p = 0.002; vs. SIM low and –high: p < 0.001, respectively), as well as between PDLLA and SIM high implants (p = 0.002) (*).
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when compared to uncoated controls.
Another possible reason for the lack of osseointegration
may have been the drug dose used, since dose-dependent
effects of statins on bone metabolism were suggested due
to differing sensitivity of osteoblasts and osteoclasts. Bone
resorption and formation were elevated with high-dose
Simvastatin while low-dose SIM decreased formation and
increased bone resorption [35]. The present results seem
contrary since SIM high rather than SIM low had bone
catabolic effects and neither exerted bone anabolic effects.
The dose-dependent, bone-anabolic effect of a comparable
SIM high-dose was previously shown to have a similar ef-
fect to that of BMP-2 in a rat fracture model [20].
Additionally, one other failure option is the type of the
incorporated drug. However, the identical substance and
coating technique were successfully investigated previously
[20]. Several other experimental studies confirmed benefi-
cial effects of statins on fracture healing using different local
application approaches [18,19,21,22]. In addition, statins
improved defect regeneration when locally applied in cranial/
mandibular bone defect models without metal implants
[15-17,36]. These studies used absorbable collagen andgelatin sponges or injections for drug delivery which
are prone to dissolve at the site of application. A femoral
defect model with local small molecule drug delivery (but
no metal implant) revealed bisphosphonates signifi-
cantly improved bone formation while lovastatin did
not [37]. Piskin et al. demonstrated Simvastatin-
loaded electrospun nanofibers enhanced bone
mineralization (histological and micro-CT analysis)
[38]. Even though the same drug was used, the different
dosage and the use of the polymer caprolactone repre-
sent different approaches than in the present setting,
hence impede comparability.
In contrast to fracture- and bone defect healing, implant
integration was investigated presently. In this regard,
different studies investigated the effect of local statin
application. A similar rodent model was utilized by
Moriyama et al. who observed improved tibial implant
integration dose-dependently after 7–14 days of local
fluvastatin-release from a PGA-coating [26]. In contrast
to the present findings, their higher-dosed group
(2.5 mg/ml) showed the best results in terms of bone
formation and push-out strength. The short observa-
tional period of 7 or 14 days may be one reason for
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day period. Further distinctions to the present study
are the chosen type of carrier and the incorporated
drug Fluvastatin (vs. Simvastatin), although both are
lipophilic, penetrate cell membranes and enhance
osteogenesis. These authors later investigated injectable
PGA-gel around tibia implants in rodents and found
similar results [28]. They observed a significant de-
crease in implant integration at one week comparable to
the present results after 56 days. However, stability
recovered and significantly increased after 14 and 28
days, respectively. Nevertheless, injected gel or mobile
nanoparticles may dissolve from the intramedullary des-
tination, while solid bioactive implant coatings may
reduce this effect.
Other experimental studies reported on improved
orthopedic implant integration in animals even under
systemical exposure to statins, administered orally [23],
percutaneously [24,27] or intraperitoneally [11,25]. Effects
were observed with up to 10-50 mg/kg bodyweight, far
exceeding the statin dose rates applied in humans, while
the equivalent dose used in humans was ineffective [25].
Hence, systemical application does not seem to be useful
for improved implant integration with normal human
drug doses. Even though one observational clinical study
reported on reduced risk of hip implant revision, deep
infection and aseptic loosening among statin users under
normal dose rates [39], no direct conclusion on the
drug was feasible. It was suggested that statin-users in
general might show a more health oriented behaviour (i.e.
medication or rehabilitation compliance). One prospect-
ively randomized clinical study found no effect on bone
healing between low Simvastatin-intake (20 mg/d orally)
and placebo [40].
Since less than 5% of an oral statin dose reaches the
circulation due to hepatic first pass elimination [29],
systemical application requires rather high drug doses.
Targeted, local application of drugs from bioactive carrier
polymers seems more efficient and may help to improve
drug availability within the bone while lowering neces-
sary drug doses, hence preventing systemic side effects.
As another potential limitation of this study, the ob-
servation period of eight weeks may be inappropriate
to observe differences in implant integration since
other authors observed effects of statins with this regard
after 7–30 days [11,25-28]. During fracture healing,
beneficial effects were reported after 5–14 days of local
statin exposure to the fracture site [18,21,22], suggest-
ing that statins cause a delayed onset of endogenous
BMP-2 production [20]. Mundy et al. reported on a quick
BMP-2 response to statins within 3–5 days in vivo and
in vitro [6] while other authors found improved implant
integration after 42–84 days following high systemical
doses of Simvastatin [23,24].After 8 weeks, remodeling “back to normal” may occur
and initial improvements in implant integration may
vanish over time. However, mid- and long term data are
important with regard to prosthetic implant integration
in humans.
Nevertheless, the timepoint does not explain the osteoly-
sis in two SIM high coated animals.
Even though the current results are discouraging with
regard to Simvastatin, local application via biocompatible,
stable drug-delivering polymers [30] seems beneficial since
no manipulations or injections to the bone are necessary.
Previous studies revealed that incorporation of several
bioactive agents (such as BMP-2, Zolendronate, Simvasta-
tin) into the PDLLA-coating of bone implants improves
fracture healing and implant integration experimentally
[20,31-34].
Conclusions
This animal study suggests impaired implant integration
under local application of Simvastatin from intramedullary
titanium implants after 8 weeks when compared to un-
coated or carrier-only coated controls.
Methods
Coating technology and growth factors
Titanium Kirschner wires (“K-wires”, Diameter 1.4 mm)
were coated with Poly(D,L-lactide), PDLLA (Boehringer,
Ingelheim, Germany), differing in the substance incor-
porated: uncoated, PDLLA, PDLLA with low-dose
Simvastatin (5.5 μg/implant, SIM low) or with high-dose
Simvastatin (90 μg/implant, SIM high). A dip coating
technique was utilized which was described in more de-
tail earlier [30].
Animals and surgery
Approval was obtained from the local Animal Experi-
mentation Ethics Committee. According to the 3R con-
cept [41], animals of the control groups (uncoated and
PDLLA) were shared with another experimental osseoin-
tegration study (data not shown here) in order to reduce
the total number of animals.
Eighty female Sprague–Dawley-Rats (mean age: 6
months, mean body weight: 260 g; Harlan-Winkelmann,
Germany) were used in the experiments. Twenty ani-
mals were randomly assigned to each of the four study
groups (n=10 specimen for biomechanical and histomor-
phometric analysis, respectively).
Animals were sedated with Isoflurane (Forene) and
intraperitoneal anesthesia using a mixture of ketamine
hydrochlorid (100 mg/mL; 80 mg/kg body weight) and
2% xylazine (12 mg/kg body weight).
After shaving the right hind leg, a 3 mm longitudinal
incision was made. Subsequently, the intercondylar
notch of the femur was opened carefully with a 1.2 mm
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the medullar cavity in a retrograde direction. The aimed
proximal position of the implant next to the greater tro-
chanter was controlled via fluoroscopy. Finally, the
remaining extending part of the implant was cut and
skin was sutured.
With regard to pain relief, all rats received buprenorphine
(TemgesicW, 0.05 mg/kg) subcutaneously for two days.
Wounds were assessed daily for clinical signs of infec-
tions. Body weight and temperature were documented
during the experimental period. Digital radiographs in
two planes were obtained at the time of surgery and
euthanasia.
After 56 days, animals of all groups were sacrificed.
The operated femurs were dissected of soft tissues and
ten femurs per group were submitted for either bio-
mechanical or histological analysis. Bones presenting
with macroscopic or radiographic signs of infection
(i.e. redness, swelling or secretion around the femoral
approach; osteolysis around the implant) underwent
sterile swabs with subsequent culture on blood agar
plates. Each 24 hours of incubation time, plates were
analyzed for growth of either aerobic or anaerobic bac-
teria over 14 days.
Biomechanical testing
Implants were exposed 3 mm proximally and distally in
each femur after careful preparation and then embedded
with bone cement (Heraeus-Kulzer, Wehrheim, Germany)
in a push-out device [32]. Subsequently, a material testing
device (Zwick 1455, Ulm, Germany) applied a constant
linear propulsion (v = 2 mm/min) to the implanted K-
wire. The peak force to loosen the implant was docu-
mented for calculating the implant-bone strength. This
maximum force was normalized to the total bone-Figure 5 Histological samples were analyzed following a 13.7 mm lin
bone/implant contact and new bone formation, within a 0.3 mm regiimplant contact area in order to minimize variation be-
tween push-out forces due to varying bone or implant
length [32]: Strength of fixation σu = Fmax/πDH [σu:
strength of fixation (Mpa), Fmax: initial push-out force
(N), D: implant diameter (mm), H: Bone length (mm)].Histomorphometry
After fixation of the bones in 10% normal buffered
formaldehyde for 2 days, dehydration in ascending
concentrations of ethanol and undecalcified embed-
ding in methylmethacrylate (Technovit 7200, Heraeus,
Wehrheim, Germany) followed.
Specimens were ground (Exakt, Norderstedt, Germany)
until implants appeared in full length with maximum
diameter. The bottom areas were glued to microscope
slides, cut into 300 μm sections with a diamond band saw
(Exakt, Norderstedt, Germany) and then ground to 80 μm.
Different stainings were used, including Safranin-O and
silvering/van Kossa (for mineralized tissues). Histological
parameters were assessed using an image analysis system
(Axioskop 40, Carl Zeiss, Goettingen, Germany). Within
the region of interest (ROI, definition: virtual line of 13.7
mm starting from the nutrient foramen [42]), direct and
indirect bone/implant contact were determined with an
analyzing software (AxioVision 4.7, Carl Zeiss, Jena,
Germany). Direct bone contact was defined as trabecu-
lar bone adjacent to the implant surface and indirect
contact when a gap existed between the implant and
bone. The ratio of direct-, indirect and total bone/implant
contact of both cortices within the ROI was calculated. Fi-
nally, new bone formation was determined as trabecular
mass within a 0.3 mm region on both sides of the implant
inside of the ROI, normalized to the total space of this
area (Figure 5).e (from the nutrient foramen to the distal femur) to determine
on of interest, on both sides of the implant [42].
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All animals were randomized in a blinded manner for
histological or biomechanical investigation. Comparison
of biomechanical and histomorphometrical data was per-
formed using Kruskal-Wallis and Mann–Whitney Test.
Tests were controlled for multiple comparison using
Bonferroni-Holm correction. Statistical differences were
defined at the 95% confidence level. Statistical software
(SPSS release 14.0, SPSS, Inc., Chicago, IL) was used for
evaluation.
Abbreviations
BMP: Bone Morphogenetic Protein; PDLLA: Poly(D,L-lactide); ROI: Region of
interest; SIM: Simvastatin.
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